Clinical trials and research have grown exponentially in the last two decades. However, despite the influx of new trials, new insights and new opportunities, the majority of would-be patients and, even, researchers have limited access to this critical information.
“Information is out there,” says Nofel Izz, Founder of Acme Clinical Trials, “but it’s virtually impossible to find. Even if you do, access tends to be limited -and often that excludes the people who need it most.”
Nofel’s Acme Clinical Trials (ACT) aims to overcome these hurdles, democratizing clinical trials and insights and providing free access and intelligent search to all users. Once logged onto AClinicalTrials.com, users can securely upload medical records and detailed form submissions which are analyzed using ACT’s AI and image recognition system. From here, patients are matched to one of more than 300,000 relevant trials, treatments and research findings. Thousands more studies are added daily.
“We’ll cull analytics and demographics of disease types along with pharmaceuticals taken,” Nofel explains. “Using AI, we’ll identify links between health conditions, medications, and trials, helping establish critical connections and, from there, establish more clear-cut success rates for specific diseases and treatment plans.”
Innovating & Accelerating ACT
Nofel founded ACT in 2017, after recognizing a glaring need in the industry. An MBA graduate of University of Cambridge with a strong computer science and innovation background, Nofel has long been involved in developing and launching new businesses. Currently, he’s involved in 19 startups, many of which focus on bringing cutting-edge tech to mainstream consumers. ACT is no exception.
The company has already received letters of intent and investment interests from Canada, China and UAE, ranging from $30 million to $55 million. The next step, Nofel explains, is choosing the right partners who will provide flexibility while facilitating growth.
Also supporting ACT will be pharmaceutical subscribers. The company anticipates more than 600 subscribers generating $15 million in revenue by 2019/20. With their subscriptions, companies will gain direct access to ACT’s analytics platform, including prescription trends, overuse patterns, industry competition and self-reported costs and effects of specific drugs by country.
In addition to investors and pharmaceutical subscribers, ACT has invited 70,000 medical specialists from around the world to add input, articles, and questionnaires to the platform.
“Our goal was to establish a powerful clinical trial and medical analytics platform free of cost and open to the public,” Nofel adds. “Now, one year later, ACT is the single largest database of active and completed clinical trials in the world. From here, we’re focused on changing the industry and, ultimately, becoming a Fortune 500 company in the healthcare analytics arena.”
This story was originally published here